GB202303663D0 - Aerosolisable formulation - Google Patents
Aerosolisable formulationInfo
- Publication number
- GB202303663D0 GB202303663D0 GBGB2303663.5A GB202303663A GB202303663D0 GB 202303663 D0 GB202303663 D0 GB 202303663D0 GB 202303663 A GB202303663 A GB 202303663A GB 202303663 D0 GB202303663 D0 GB 202303663D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- aerosolisable formulation
- aerosolisable
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2303663.5A GB202303663D0 (en) | 2023-03-13 | 2023-03-13 | Aerosolisable formulation |
PCT/GB2023/051637 WO2023247962A1 (en) | 2022-06-24 | 2023-06-22 | Aerosolisable formulation |
KR1020247042618A KR20250016261A (en) | 2022-06-24 | 2023-06-22 | Aerosolizable formulations |
EP23736448.4A EP4543230A1 (en) | 2022-06-24 | 2023-06-22 | Aerosolisable formulation |
JP2024573958A JP2025520549A (en) | 2022-06-24 | 2023-06-22 | Aerosolizable Formulations |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2303663.5A GB202303663D0 (en) | 2023-03-13 | 2023-03-13 | Aerosolisable formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
GB202303663D0 true GB202303663D0 (en) | 2023-04-26 |
Family
ID=86052754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB2303663.5A Pending GB202303663D0 (en) | 2022-06-24 | 2023-03-13 | Aerosolisable formulation |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB202303663D0 (en) |
-
2023
- 2023-03-13 GB GBGB2303663.5A patent/GB202303663D0/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL319149A (en) | Upadacitinib formulation | |
GB202007546D0 (en) | Formulation | |
IL307849A (en) | Sotorasib formulation | |
GB202318884D0 (en) | Formulation | |
GB202316857D0 (en) | Cannabinoid-based formulation | |
GB202312814D0 (en) | Formulation | |
GB202312220D0 (en) | Formulation | |
GB202311622D0 (en) | Formulation | |
GB202311439D0 (en) | Formulation | |
IL317857A (en) | Orellanine formulation | |
GB202308224D0 (en) | Formulation | |
GB202306990D0 (en) | Cannabinoid-based formulation | |
GB202306995D0 (en) | Cannabinoid-based formulation | |
GB202307002D0 (en) | Cannabinoid-based formulation | |
GB202307003D0 (en) | Cannabinoid-based formulation | |
GB202303663D0 (en) | Aerosolisable formulation | |
GB202218160D0 (en) | Formulation | |
GB202217857D0 (en) | Formulation | |
GB202217267D0 (en) | Aerosolisable formulation | |
GB202217148D0 (en) | Formulation | |
GB202216335D0 (en) | Formulation | |
GB202213663D0 (en) | Aerosolisable formulation | |
GB202211203D0 (en) | Formulation | |
GB202209298D0 (en) | Aerosolisable formulation | |
GB202211231D0 (en) | Novel formulation |